The Future of Radioembolization
Transform oncology embolization therapy and improve treatment options available to patients
© 2024 nedmedical.com
Liver cancer diagnosis each year in the US
Global deaths from liver cancer each year
5-year overall survival
We must do better.
Liver cancer is one of the leading causes of global cancer deaths with an abysmal 5-year survival of 15.6%. In the latest Annual Report to the Nation from the NIH, Liver cancer is one of four cancers that has shown no improvement in death rates for both men and women in the United States. In addition, in a recent JAMA Oncology publication, Liver cancer is projected to cost the global economy $1.7 trillion by 2050.
One of the most common treatments for liver cancer is radioembolization therapy. Despite decades of commercial traction and strong business fundamentals, radioembolization continues to be a palliative monotherapy with limited patient outcomes.
NED Medical is looking to change the current trajectory of liver disease and aims to provide clinicians and patients with improved treatment options.
CombiSphere is a Y90 radioembolization therapy made with proprietary materials that provide a unique combination of characteristics that include:
Optimized size & density
Optimized emission activity per particle
Optimized tumor coverage
• Interventional Radiologist
• 17+ years in clinical practice
• Vascular & Interventional Radiologist
• 15+ years in clinical practice